Ohr releases new interim data on Squalamine eye drops

Ohr Pharmaceuticals reported additional interim data from its phase 2 study on Squalamine eye drops for the treatment of wet age-related macular degeneration. Data showed eyes that received a combination of Squalamine eye drops (OHR-102) and as-needed dosing of Lucentis (ranibizumab, Genentech) had visual acuity and anatomical benefits compared with patients who received placebo eye drops in combination with as-needed dosing of ranibizumab. Jason S. Slakter, MD, chief medical officer of Ohr, presented the new interim data at the American Society of Retina Specialists annual meeting.

Full Story →